Table 2 Clinical characteristics of the erdafitinib-treated cohort
n = 21 patients | ||
|---|---|---|
Age at erdafitinib start, median years (range) | 67 (48–77) | |
Sex | Female | 7 (33%) |
Male | 14 (67%) | |
Location of primary | Kidney/renal pelvis | 7 (33%) |
Ureter | 3 (14%) | |
Bladder | 11 (52%) | |
ECOG performance status prior to erdafitinib initiation | 1 | 6 (29%) |
2 | 3 (14%) | |
3 | 1 (5%) | |
Not available | 9 (43%) | |
Line of treatment for erdafitinib | 2L | 9 (43%) |
3L | 6 (29%) | |
4L | 1 (5%) | |
5L | 3 (14%) | |
Not available | 2 (10%) | |
Best response | Complete response | 1 (5%) |
Partial response | 5 (24%) | |
Stable disease | 8 (38%) | |
Progression | 6 (29%) | |
Not assessed | 1 (5%) | |
Reason for treatment discontinuation | Progression | 11 (52%) |
Toxicity | 6 (29%) | |
Ongoing treatment | 3 (14%) | |
Death | 1 (5%) |
